No Name, American Greed: Congressman Guilty of Insider Trading

[Image]( EMAIL}/redirect (Advertisement) Posted on December 17th, 2019 By Kyle Dennis on Raging Bull Another day, another scandal. When’s the last time you turned on the news and didn’t hear about some politicians who cheated the public? I can’t recall either. The problem with politicians is that they’re CONNECTED… and rather than serve the public, they take care of number one first — themselves. And while we’re breaking our backs, working hard for our tax dollars, they are off spending it any way they feel like. It seems like they live by the mantra: It’s not considered cheating if you don’t get caught… If you think Raj Rajaratnam, SAC Capital or Goldman Sachs was bad… some politicians are on another level. Don’t believe me? In this issue of American Greed, you’ll learn about a congressman who fell in love with big pharma — and got so deep he was later charged with insider trading. What makes this case even more shocking is that it was a family affair — the future in-laws were in on it! Talk about the apple not falling far from the tree. EMAIL}/redirect (Advertisement) The Australian biotech company Innate Immunotherapeutics Ltd. is at the center of this scandal. Not for any wrongdoing but because of one of its independent directors, U.S. Representative Christopher Collins. Innate was developing a drug for multiple sclerosis. Their clinical trial results and research were kept solely within the company. Christopher Collins was a groundbreaking congressman, and the very first U.S. Representative to endorse President Donald Trump. He also now holds a different title, as the first member of a sitting member congress to be charged and convicted of insider-trading. Christopher Collins is a very wealthy man who had been sitting on the board of directors, and a large stakeholder of Innate shares. At one point, the Collins family owned a third of the company. Collins even had a hand in its IPO in Australia. To add to Collins’s questionable litigation behavior, he also was a huge Big Pharma supporter. He sponsored several bills that would benefit Innate—a dangerous cocktail that would later get him in trouble. Collins was doing his part, but there were some things he couldn’t control—the drug testing results. Innate’s multiple sclerosis drug was a clinical failure. Even going as far as saying there were no “significant differences in [outcomes] between MIS416 and placebo”. Which is about as big of a failure as you can get other than your drug have adverse effects. EMAIL}/redirect (Advertisement) How The Congressman Actually Avoided A $570K Loss Christopher replied to this news “Wow. Makes no sense. How are these results even possible?” Immediately following this email Christopher called his son Cameron Collins during which he divulged confidential information that Innate’s only drug was a failure. Christopher Collins and his son knew what this would do to the company’s stock. The morning after the call took place Cameron began to sell his shares based of the insider information. During June 23 and 26 of 2017, Cameron Collins sold 1,391,500 shares of Innate. After his father’s phone call Cameron called his fiancée and told her that Innate drug trial was a failure, further spreading the inside knowledge. Cameron avoided a loss of $570,900 and his fiancée’s father avoided a loss of $186,620 all because of insider trading. Everyone not in the know suffered financially from the drug’s failure. A day before Christopher Collins planned to plead guilty to the criminal charges of insider trading, he sent a letter to, at the time, House Speaker Nancy Pelosi that he resigned ending the term “effective immediately”. Unlike many times where the culprit flies under the radar, these men were caught and hung out to dry. An example that even members of Congress aren’t untouchable. The three men agreed to disgorge their avoided losses with prejudgment interest. A perfect judgment that they would receive the same losses than many Innate shareholders felt. Perfect karmic justice. Take A Hint This story has a large part to play. It’s not just insider trading, it’s the quess you can pick up when watching trades. Completely innocent of any wrongdoing you see that someone out of nowhere sold over a million shares of their stock. Something is up. This exactly where you want to take a hit and sell too. Or the opposite, you see that someone out there is gobbling up shares like samples from the yogurt shop. Innocent of whatever set off their big move, you can take a hint and get in on the action too. The thing is… this happens ALL the time in the markets. These “insiders” have found new ways to hide their trades in the options market, in an attempt to make trades based on insider information. However, what they don’t know is the fact there are scanners out there that detect their every move. EMAIL}/redirect (Advertisement) To get Exclusive Offers make sure you grab your cellphone (which you are probably doing right now) and join our VIP text messaging list (standard text and messaging rates may apply)to make it even easier, if you are on your cell phone now click this Button Below: [SIGN ME UP NOW]( © 2019 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( | [Change Subscriber Options](